ALMIRALL, S.A. «12345...» Page 2 out of 16 04/01/2024 17:36 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el cuarto trimestre de 2023 Register number: 26061 12/12/2023 07:59 ALMIRALL, S.A. On business and financial situation Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology Register number: 25748 17/11/2023 11:55 ALMIRALL, S.A. On business and financial situation Almirall receives European Commission approval of EBGLYSS® (lebrikizumab) for moderate-to-severe atopic dermatitis Register number: 25456 09/11/2023 06:59 ALMIRALL, S.A. On business and financial situation Almirall files Nine Months 2023 Results Presentation Register number: 25298 09/11/2023 06:56 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain Nine Months 2023 Results Presentation. Register number: 25297 30/10/2023 10:00 ALMIRALL, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 25130 23/10/2023 16:44 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el tercer trimestre de 2023 Register number: 24989 12/10/2023 07:00 ALMIRALL, S.A. On business and financial situation Almirall and EpimAb Biotherapeutics Announce Bispecific Antibody License Agreement Register number: 24863 03/10/2023 09:35 ALMIRALL, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 24718 15/09/2023 14:40 ALMIRALL, S.A. On business and financial situation EBGLYSS® (lebrikizumab) receives positive CHMP opinion for moderate-to-severe atopic dermatitis. Register number: 24473 Page 2 out of 16 «12345...»
